


Ask a doctor about a prescription for Binabic
Bicalutamide
Bicalutamide, the active substance of Binabic, belongs to a group of medicines called anti-androgens.
Contact your doctor if you do not feel better or if you feel worse.
Before starting treatment with Binabic, discuss with your doctor if:
If you are admitted to hospital, inform the medical staff that you are taking Binabic.
Inform your doctor if you have any of the following conditions:
any heart or blood vessel disease, including irregular heart rhythm (arrhythmia) or if you are being treated with medicines for these conditions. During treatment with Binabic, there may be an increased risk of irregular heart rhythm.
Tell your doctor about all the medicines you are taking now or have taken recently, and about any medicines you plan to take.
Do not take Binabic if you are already taking the following medicines:
Inform your doctor if you are taking any of the following medicines:
Binabic may interfere with the action of certain medicines used to treat irregular heart rhythm (e.g., quinidine, procainamide, amiodarone, and sotalol) or may increase the risk of irregular heart rhythm when taken with certain other medicines (e.g., methadone (used for pain relief and in detoxification programs), moxifloxacin (an antibiotic), or medicines used to treat serious mental illnesses).
Binabic should not be taken by women. You should not take Binabic if you are pregnant or breast-feeding.
It is unlikely that Binabic will affect your ability to drive or use machines. However, as drowsiness may occur when taking Binabic, be cautious if this symptom occurs.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, which is essentially "sodium-free".
Always take Binabic exactly as your doctor has told you. If you are not sure, ask your doctor.
Binabic should not be given to patients under 18 years of age.
If you have taken more than the prescribed dose of Binabic, contact your doctor or go to the hospital immediately.
Like all medicines, Binabic can cause side effects, although not everybody gets them.
Uncommon (affects less than 1 in 100 people). Symptoms may include:
Side Effects:
Very Common(affects more than 1 in 10 people)
Uncommon(affects less than 1 in 100 people)
Very Common(affects more than 1 in 10 people)
Common(affects less than 1 in 10 people)
The above list of possible side effects is not exhaustive, and you may not experience any of them. If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist.
If you experience any side effects, including those not listed in this leaflet, tell your doctor, nurse, or pharmacist.
Side effects can be reported directly to the Department for Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C
PL-02 222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicinal product out of the sight and reach of children.
No special precautions for storage are necessary.
Do not use Binabic after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Binabic are white, round, biconvex film-coated tablets.
The pack contains 28 film-coated tablets packaged in PVC/PVDC/Aluminum blisters.
For more detailed information, contact the marketing authorization holder or the parallel importer.
Vipharm S.A.
ul. A. i F. Radziwiłłów 9
05-850 Ożarów Mazowiecki
Poland
Genepharm S.A.
18th klm Marathonos Avenue
153 51 Pallini Attikis
Greece
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in the Czech Republic, the country of export: 44/569/08-C
Parallel import authorization number: 192/25
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Poland Binabic 50 mg
Czech Republic Binabic 50 mg
Slovakia Binabic 50 mg
[Information about the trademark]
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Binabic – subject to medical assessment and local rules.